T-Cell Therapy for Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic HER2-negative Breast
Interventions: DRUG: Cyclophosphamide|BIOLOGICAL: Mesothelin-targeted T cells|DRUG: AP1903
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: United States Department of Defense